Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A glimpse into the genetic basis of schizophrenia

25.07.2014

Novel genetic associations might enlighten underlying molecular mechanisms of schizophrenia and provide biomarkers for future diagnosis

For schizophrenia, biomarkers or supportive diagnostic tests are scarce and for many patients the efficacy of pharmacological treatment is limited. The PGC-SZ (Psychiatric Genomics Consortium - Schizophrenia), including scientists from the Max Planck Institute of Psychiatry in Munich, has now identified more than 100 genetic loci related to schizophrenia.


Artistic view of how life feels after the diagnosis of schizophrenia.

© Glen Brady, Queensland Centre for Mental Health Research

The results point to molecules that are currently the most promising targets for therapeutics also aligning well with recent theories about factors causing schizophrenia. The novel findings provide a relevant foundation for mechanistic and treatment development studies.

Schizophrenia is known to be a heritable disorder, highlighting inherited genetic variants to be a key causative for this disease. Due to the scarcity of biomarkers or supportive diagnostic tests, diagnosis is almost exclusively clinician-based. Furthermore, although pharmacological treatments are available for schizophrenia, their efficacy is limited for many patients.

The PGC-SZ, including Bertram Müller-Myhsok, Research Group Leader at the Max Planck Institute of Psychiatry in Munich, has now performed a genome-wide association study and identified more than 100 genomic loci that are significantly related to schizophrenia.

“Our findings include molecules that are currently the most promising targets for therapeutics and point to molecular systems aligning with the predominant theories on factors causing schizophrenia,” states Bertram Müller-Myhsok. “This might suggest that the many novel findings we report also provide a relevant foundation for treatment development studies.”

Particularly variations in genes related to altered glutamatergic synaptic and calcium channel function might serve as a panel of biomarkers for future diagnosis of schizophrenia or might allow better understanding of the molecular mechanisms underlying the disease.

Such associations with genes playing a role in the central nervous system are most relevant for the development of treatment strategies. The results of the study verified genetic associations with the gene coding for the type 2 dopaminergic receptor (DRD2).

“All available antipsychotic drugs are thought to exert their main therapeutic effects through blockade of DRD2,” explains Bertram Müller-Myhsok. “Since the discovery of this mechanism over 60 years ago, no new antipsychotic drug of proven efficacy has been developed based on other target molecules.” Thus, therapeutic stasis is in large part a consequence of the fact that the disease-causing mechanisms are still unknown. Identifying the causes of schizophrenia is therefore a critical step towards improving treatment and outcome for patients suffering from this disorder.

Contact 

Dr. Bertram Müller-Myhsok

Max Planck Institute of Psychiatry, München

Phone: +49 89 30622-246

 

Anna Niedl

Press and Public Relations

Max Planck Institute of Psychiatry, München

Phone: +49 89 30622-263
Fax: +49 89 30622-370

 

Original publication

 
Schizophrenia Working Group of the Psychiatric Genomics Consortium.
Biological insights from 108 schizophrenia-associated genetic loci.
Nature, 22. Juli 2014 (doi:10.1038/nature13595)AN/HR

Dr. Bertram Müller-Myhsok | Max-Planck-Institute

Further reports about: Psychiatry biomarkers disorder findings mechanisms schizophrenia therapeutic

More articles from Life Sciences:

nachricht Rice University lab runs crowd-sourced competition to create 'big data' diagnostic tools
30.06.2016 | Rice University

nachricht A protein coat helps chromosomes keep their distance
30.06.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Thousands on one chip: New Method to study Proteins

Since the completion of the human genome an important goal has been to elucidate the function of the now known proteins: a new molecular method enables the investigation of the function for thousands of proteins in parallel. Applying this new method, an international team of researchers with leading participation of the Technical University of Munich (TUM) was able to identify hundreds of previously unknown interactions among proteins.

The human genome and those of most common crops have been decoded for many years. Soon it will be possible to sequence your personal genome for less than 1000...

Im Focus: Optical lenses, hardly larger than a human hair

3D printing enables the smalles complex micro-objectives

3D printing revolutionized the manufacturing of complex shapes in the last few years. Using additive depositing of materials, where individual dots or lines...

Im Focus: Flexible OLED applications arrive

R2D2, a joint project to analyze and development high-TRL processes and technologies for manufacture of flexible organic light-emitting diodes (OLEDs) funded by the German Federal Ministry of Education and Research (BMBF) has been successfully completed.

In contrast to point light sources like LEDs made of inorganic semiconductor crystals, organic light-emitting diodes (OLEDs) are light-emitting surfaces. Their...

Im Focus: Unexpected flexibility found in odorant molecules

High resolution rotational spectroscopy reveals an unprecedented number of conformations of an odorant molecule – a new world record!

In a recent publication in the journal Physical Chemistry Chemical Physics, researchers from the Max Planck Institute for the Structure and Dynamics of Matter...

Im Focus: 3-D printing produces cartilage from strands of bioink

Strands of cow cartilage substitute for ink in a 3D bioprinting process that may one day create cartilage patches for worn out joints, according to a team of engineers. "Our goal is to create tissue that can be used to replace large amounts of worn out tissue or design patches," said Ibrahim T. Ozbolat, associate professor of engineering science and mechanics. "Those who have osteoarthritis in their joints suffer a lot. We need a new alternative treatment for this."

Cartilage is a good tissue to target for scale-up bioprinting because it is made up of only one cell type and has no blood vessels within the tissue. It is...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Quantum technologies to revolutionise 21st century - Nobel Laureates discuss at Lindau

30.06.2016 | Event News

International Conference ‘GEO BON’ Wants to Close Knowledge Gaps in Global Biodiversity

28.06.2016 | Event News

ERES 2016: The largest conference in the European real estate industry

09.06.2016 | Event News

 
Latest News

Modeling NAFLD with human pluripotent stem cell derived immature hepatocyte like cells

30.06.2016 | Health and Medicine

Rice University lab runs crowd-sourced competition to create 'big data' diagnostic tools

30.06.2016 | Life Sciences

A drop of water as a model for the interplay of adhesion and stiction

30.06.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>